Edgewise Therapeutics (EWTX) Total Liabilities (2020 - 2026)

Edgewise Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $25.3 million in Q1 2026.

• Quarterly Total Liabilities rose 2.62% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.3 million (up 2.62% YoY) and the FY2025 annual result came in at $30.3 million, up 9.95% from the prior year.
• Total Liabilities fell to $25.3 million in Q1 2026 per EWTX's latest filing, from $30.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $30.3 million in Q4 2025 and troughed at $11.0 million in Q2 2022.
• A 5-year average of $21.1 million and a median of $21.2 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 87.88% in 2022, down 96.36% in 2022.
• Over 5 years, Total Liabilities stood at $20.4 million in 2022, then gained by 4.02% to $21.2 million in 2023, then jumped by 30.16% to $27.6 million in 2024, then grew by 9.95% to $30.3 million in 2025, then decreased by 16.57% to $25.3 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $25.3 million, $30.3 million, and $24.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.